Arima Genomics - About the company
Arima Genomics is a series C company based in San Diego (United States), founded in 2015 by William Alaynick and Siddarth Selvaraj. It operates as a Developer of technologies for genome sequence and structure. Arima Genomics has raised $29M in funding from investors like Tech Coast Angels, Agilent and Co-win Ventures. The company has 477 active competitors, including 133 funded and 100 that have exited. Its top competitors include companies like Guardant Health, Natera and Foundation Medicine.
Company Details
Developer of technologies for genome sequence and structure. Arima Genomics is developing a novel method of DNA sequencing that enables genome-scale phasing or haplotyping of DNA variants using a combination of proximity ligation (Hi-C), short-read DNA sequencing, and a proprietary probabilistic algorithm for haplotype assembly. The company calls its new method, HaploSeq, and is derived from work done by Selvaraj et al (Nature Biotechnology, 2013, Vol 31, pp-1111). The method addresses a currently unmet need for cost-effective and reliable methods for the phasing of variants. Arima has multiple SIBR grants from the Department of Health and human services to develop their method.
- Website
- arimagenomics.com
- Social
Key Metrics
Founded Year
2015
Location
San Diego, United States
Stage
Series C
Total Funding
$29M in 12 rounds
Latest Funding Round
Investors
Ranked
19th among 477 active competitors
Employee Count
43 as on Aug 31, 2026
Similar Companies
Sign up to download Arima Genomics' company profile
Arima Genomics's funding and investors
Arima Genomics has raised a total funding of $29M over 12 rounds. Its first funding round was on Mar 01, 2015. Its latest funding round was a Grant (prize money) round on Sep 04, 2025 for $*****. 1 investor participated in its latest round. Arima Genomics has 10 institutional investors and 2 angel investors.
Here is the list of recent funding rounds of Arima Genomics:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Sep 04, 2025 | 3583519 | Grant (prize money) | 4330714 | 7375882 | 5407382 | 6084356 |
Jun 26, 2025 | 4427257 | Series C | 4284637 | 9047084 | 6559281 | |
Feb 15, 2023 | 8673252 | Grant (prize money) | 9118231 | 4871653 | 6704866 |
Access funding benchmarks and valuations. Sign up today!View details of Arima Genomics's funding rounds and investors
Arima Genomics' founders and board of directors
Founder? Claim ProfileThe founders of Arima Genomics are William Alaynick and Siddarth Selvaraj.
Here are the details of Arima Genomics' key team members:
- William Alaynick: Co-Founder & COO of Arima Genomics and founder of 2 other companies, Defined Bioscience and Metabolus. They serve on the board of 1 company.
- Siddarth Selvaraj: Co-Founder & CEO of Arima Genomics. Contact Info: 1 email address
View details of Arima Genomics's Founder profiles and Board Members
Arima Genomics' employee count trend
Arima Genomics has 43 employees as of Aug 26. Here is Arima Genomics's employee count trend over the years:
Uncover Arima Genomics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Arima Genomics's Competitors and alternates
Top competitors of Arima Genomics include Guardant Health, Natera and Foundation Medicine. Here is the list of Top 10 competitors of Arima Genomics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Guardant Health 2012, Redwood City (United States), Public | Developer of digital sequencing technology for cancer detection | $557M | 79/100 | |
2nd | Natera 2004, Redwood City (United States), Public | Developer of cell-free DNA testing for oncology, women’s health, and organ health | $152M | 77/100 | |
3rd | Foundation Medicine 2010, Cambridge (United States), Acquired | Provider of genomics-based diagnostics test for cancer | $96.5M | 70/100 | |
4th | Online platform for genetic and diagnostic health testing that helps identify health risks | $67.6M | 69/100 | ||
5th | BillionToOne 2015, San Francisco (United States), Public | Provider of cell-free cancer liquid biopsy test | $389M | 69/100 | |
6th | Myriad Genetics 1991, United States, Public | Developer of molecular diagnostics and personalized medicine for cancer | - | 68/100 | |
7th | Caris Life Sciences 1996, Irving (United States), Public | Developer of panomic disease profiling technologies for cancer precision medicine | $1.23B | 66/100 | |
8th |  Foresight Diagnostics 2020, Aurora (United States), Acquired | Developer of minimally-invasive liquid biopsy test for the detection of cancer | $104M | 66/100 | |
9th | Saga Diagnostics 2016, Morrisville (United States), Acquired | Provider of tests for detection and analysis of circulating tumor DNA | $17.9M | 64/100 | |
10th | Delfi Diagnostics 2019, Baltimore (United States), Series B | Provider of DNA sequencing for cancer detection | $332M | 64/100 | |
19th | Arima Genomics 2015, San Diego (United States), Series C | Developer of technologies for genome sequence and structure | $29M | 58/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Arima Genomics's competitors? Click here to see the top ones
Arima Genomics's Investments and acquisitions
Arima Genomics has made no investments or acquisitions yet.
Reports related to Arima Genomics
Here is the latest report on Arima Genomics's sector:
News related to Arima Genomics
Filter this listMedia has covered Arima Genomics for a total of 6 events in the last 1 year, 3 of them have been about company updates and 1 about partnerships.
•
•
Arima Genomics Named to Fast Company’s 2026 World Changing Ideas List for Aventa Lymphoma TestBusiness Wire•Jun 16, 2026•Arima Genomics
•
Arima Genomics Announces AACR 2026 Presentations Across Solid TumorsBusiness Wire•Apr 15, 2026•Arima Genomics
•
•
Arima Genomics Announces Data Presentation at the Association for Molecular Pathology 2025Business Wire•Nov 13, 2025•Arima Genomics
•
Arima Genomics Wins BioTech Breakthrough Award For “Clinical Diagnostics Solution of the Year”Business Wire•Nov 06, 2025•Arima Genomics
•
Arima Genomics Launches Aventa Lymphoma Test for B- and T-Cell Lymphoma DiagnosisBusiness Wire•Sep 03, 2025•Arima Genomics
•
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Arima Genomics
Explore our recently published companies
- My Mood - United Kingdom based, Unfunded company
- Seminole Nation Division of Commerce - United States based, 2010 founded, Funding Raised company
- River Basin - New Orleans based, Unfunded company
- Inverdia - Unfunded company
- Chisonultrasound - Unfunded company
- Ed Foundry - 2023 founded, Unfunded company
